









Markets
/
Stocks
/
nasdaq-aimd
/

Ainos Inc

AIMD

1.910USD

-0.040-2.05%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

9.16MMarket Cap

LossP/E TTM



Ainos Inc

1.910

-0.040-2.05%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ainos Inc

Currency: USD Updated: 2026-02-06

Key Insights

Ainos Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 217 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is high.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ainos Inc's Score

Industry at a Glance

Industry Ranking

217 / 392

Overall Ranking

446 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ainos Inc Highlights

StrengthsRisks

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.

Growing

The company is in a growing phase, with the latest annual income totaling USD 20.73K.

Fairly Valued

The company’s latest PE is -0.49, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 24.23K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.38.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Ainos Inc is 6.52, ranking 246 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.52

Change



Financials

4.73

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.29

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.08

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.47

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ainos Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Ainos Inc is 6.63, ranking 245 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.48, which is -70.08% below the recent high of -0.15 and -256.49% above the recent low of -1.73.

Score

Industry at a Glance

Previous score

6.63

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 217/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Ainos Inc. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Ainos Inc is 6.41, ranking 252 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.35 and the support level at 1.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.51

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.030

Neutral

RSI(14)

47.023

Neutral

STOCH(KDJ)(9,3,3)

35.350

Sell

ATR(14)

0.263

High Vlolatility

CCI(14)

-40.141

Neutral

Williams %R

72.368

Sell

TRIX(12,20)

0.314

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.068

Sell

MA10

2.027

Sell

MA20

1.956

Sell

MA50

2.009

Sell

MA100

2.670

Sell

MA200

2.833

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Taiwan Carbon Nano Technology Corp

1.04M

-1.02%

Ainos Inc

491.26K

Tsai (Chun-Hsien)

410.37K

+24.22%

Lee (Ting Chuan)

365.71K

+28.00%

Tsai (Chun-Jung)

357.00K

+28.88%

chang (wen-han)

101.55K

+97.00%

chiang (yao-chung)

91.28K

+121.12%

Wei (Pao- Sheng)

90.88K

+122.31%

Tsai (Chung-Yi)

90.88K

+122.31%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ainos Inc is 2.14, ranking 251 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.38. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.